Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
Sponsor: Pfizer
This PHASE4 trial investigates Arthritis, Rheumatoid and is currently completed. Pfizer leads this study, which shows 42 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
42 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE4
-
Dec 2025 — Feb 2026 [monthly]
Completed PHASE4
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
▶ Show 37 earlier versions
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2021 — Sep 2021 [monthly]
Completed PHASE4
-
May 2021 — Jun 2021 [monthly]
Completed PHASE4
-
Apr 2021 — May 2021 [monthly]
Completed PHASE4
-
Mar 2021 — Apr 2021 [monthly]
Completed PHASE4
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE4
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Nov 2020 — Dec 2020 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jul 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE4
-
Apr 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE4
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE4
-
Nov 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE4
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE4
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE4
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE4
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE4
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE4
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE4
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE4
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE4
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE4
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE4
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE4
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE4
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE4
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE4
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE4
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE4
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE4
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE4
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE4
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE4
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amarillo, United States , Amman, Jordan , Ankara, Turkey (Türkiye) , Arequipa, Peru , Ashkelon, Israel , Atlanta, United States , Auckland, New Zealand , Austin, United States , Aydin, Turkey (Türkiye) , Bangkok, Thailand and 257 more locations